Literature DB >> 25720821

N-acetyl-S-(N,N-diethylcarbamoyl) cysteine in rat nucleus accumbens, medial prefrontal cortex, and in rat and human plasma after disulfiram administration.

Robert D Winefield1, Anthonius A M Heemskerk2, Swetha Kaul3, Todd D Williams4, Michael J Caspers5, Thomas E Prisinzano5, Elinore F McCance-Katz6, Craig E Lunte5, Morris D Faiman7.   

Abstract

Disulfiram (DSF), a treatment for alcohol use disorders, has shown some clinical effectiveness in treating addiction to cocaine, nicotine, and pathological gambling. The mechanism of action of DSF for treating these addictions is unclear but it is unlikely to involve the inhibition of liver aldehyde dehydrogenase (ALDH2). DSF is a pro-drug and forms a number of metabolites, one of which is N-acetyl-S-(N,N-diethylcarbamoyl) cysteine (DETC-NAC). Here we describe a LCMS/MS method on a QQQ type instrument to quantify DETC-NAC in plasma and intracellular fluid from mammalian brain. An internal standard, the N,N-di-isopropylcarbamoyl homolog (MIM: 291>128) is easily separable from DETC-NAC (MIM: 263>100) on C18 RP media with a methanol gradient. The method's linear range is 0.5-500 nM from plasma and dialysate salt solution with all precisions better than 10% RSD. DETC-NAC and internal standards were recovered at better than 95% from all matrices, perchloric acid precipitation (plasma) or formic acid addition (salt) and is stable in plasma or salt at low pH for up to 24 h. Stability is observed through three freeze-thaw cycles per day for 7 days. No HPLC peak area matrix effect was greater than 10%. A human plasma sample from a prior analysis for S-(N,N-diethylcarbamoyl) glutathione (CARB) was found to have DETC NAC as well. In other human plasma samples from 62.5 mg/d and 250 mg/d dosing, CARB concentration peaks at 0.3 and 4 nM at 3 h followed by DETC-NAC peaks of 11 and 70 nM 2 h later. Employing microdialysis sampling, DETC-NAC levels in the nucleus accumbens (NAc), medial prefrontal cortex (mPFC), and plasma of rats treated with DSF reached 1.1, 2.5 and 80 nM at 6h. The correlation between the appearance and long duration of DETC-NAC concentration in rat brain and the persistence of DSF-induced changes in neurotransmitters observed by Faiman et al. (Neuropharmacology, 2013, 75C, 95-105) is discussed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carbamathione; DETC-NAC; Disulfiram; Mercapturate pathway; Substance abuse disorders

Mesh:

Substances:

Year:  2015        PMID: 25720821      PMCID: PMC4410022          DOI: 10.1016/j.jpba.2015.01.036

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  17 in total

1.  Identification of the human and rat P450 enzymes responsible for the sulfoxidation of S-methyl N,N-diethylthiolcarbamate (DETC-ME). The terminal step in the bioactivation of disulfiram.

Authors:  A Madan; A Parkinson; M D Faiman
Journal:  Drug Metab Dispos       Date:  1995-10       Impact factor: 3.922

2.  Dose-effect relationship of disulfiram in human volunteers. II: A study of the relation between the disulfiram-alcohol reaction and plasma concentrations of acetaldehyde, diethyldithiocarbamic acid methyl ester, and erythrocyte aldehyde dehydrogenase activity.

Authors:  B Johansson; H R Angelo; J K Christensen; I W Møller; P Rønsted
Journal:  Pharmacol Toxicol       Date:  1991-03

3.  Studies on the metabolic activation of disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of urinary N-acetylcysteine conjugates.

Authors:  P Hu; L Jin; T A Baillie
Journal:  J Pharmacol Exp Ther       Date:  1997-05       Impact factor: 4.030

4.  Comparative aspects of disulfiram and its metabolites in the disulfiram-ethanol reaction in the rat.

Authors:  J J Yourick; M D Faiman
Journal:  Biochem Pharmacol       Date:  1989-02-01       Impact factor: 5.858

5.  Disulfiram, an option for the treatment of pathological gambling?

Authors:  Jochen Mutschler; Mira Bühler; Martin Grosshans; Alexander Diehl; Karl Mann; Falk Kiefer
Journal:  Alcohol Alcohol       Date:  2010-01-18       Impact factor: 2.826

6.  Disulfiram metabolism as a requirement for the inhibition of rat liver mitochondrial low Km aldehyde dehydrogenase.

Authors:  J J Yourick; M D Faiman
Journal:  Biochem Pharmacol       Date:  1991-09-12       Impact factor: 5.858

Review 7.  Glutathione conjugation and conversion to mercapturic acids can occur as an intrahepatic process.

Authors:  C A Hinchman; N Ballatori
Journal:  J Toxicol Environ Health       Date:  1994-04

8.  Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.

Authors:  Kathleen M Carroll; Lisa R Fenton; Samuel A Ball; Charla Nich; Tami L Frankforter; Julia Shi; Bruce J Rounsaville
Journal:  Arch Gen Psychiatry       Date:  2004-03

9.  Identification of novel glutathione conjugates of disulfiram and diethyldithiocarbamate in rat bile by liquid chromatography-tandem mass spectrometry. Evidence for metabolic activation of disulfiram in vivo.

Authors:  L Jin; M R Davis; P Hu; T A Baillie
Journal:  Chem Res Toxicol       Date:  1994 Jul-Aug       Impact factor: 3.739

10.  In vitro and in vivo inhibition of rat liver aldehyde dehydrogenase by S-methyl N,N-diethylthiolcarbamate sulfoxide, a new metabolite of disulfiram.

Authors:  B W Hart; M D Faiman
Journal:  Biochem Pharmacol       Date:  1992-02-04       Impact factor: 5.858

View more
  3 in total

1.  Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels.

Authors:  Patricia Di Ciano; Daniel F Manvich; Abhiram Pushparaj; Andrew Gappasov; Ellen J Hess; David Weinshenker; Bernard Le Foll
Journal:  Psychopharmacology (Berl)       Date:  2017-10-30       Impact factor: 4.530

Review 2.  Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?

Authors:  Carolina L Haass-Koffler; Fatemeh Akhlaghi; Robert M Swift; Lorenzo Leggio
Journal:  J Psychopharmacol       Date:  2017-01-16       Impact factor: 4.153

3.  Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's disease hallmarks.

Authors:  Sven Reinhardt; Nicolai Stoye; Mathias Luderer; Falk Kiefer; Ulrich Schmitt; Klaus Lieb; Kristina Endres
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.